; (ii) the Chief Actuary of the Centers for Medicare & Medicaid Services certifies that such expansion would reduce (or would not result in any increase in) net program spending under this title; and (iii) the Secretary determines that such expansion would not deny or limit the coverage or provision of benefits under this title for applicable individuals. (7) Consultation with stakeholders (A) In general The Secretary shall consult with stakeholders regarding the establishment and implementation of the CKD early detection and treatment demonstration program. (B) Timing of consultation The Secretary shall begin to consult with stakeholders pursuant to subparagraph (A) not later than six months after the date of the enactment of this section. (8) Definitions For purposes of this section, the following definitions apply: (A) CKD–EDT practitioner Subject to paragraph (9), the term CKD–EDT practitioner means, with respect to an enrolled CKD–EDT individual, a physician, nurse practitioner, or physician assistant who— (i) is the primary care practitioner for such individual; (ii) agrees, with respect to each fiscal year in which the practitioner participates in the CKD early detection and treatment demonstration program, to— (I) assess the at-risk patient populations of such physician, nurse practitioner, or physician assistant (as applicable) for chronic kidney disease pursuant to published clinical practice guidelines with respect to chronic kidney disease; and (II) submit to the Secretary the results of the assessments described in subclause (I); (iii) uses certified EHR technology (as defined in section 1833(o)(4)); (iv) elects to participate in the CKD early detection and treatment demonstration program with respect to all enrolled CKD–EDT individuals for whom such physician, nurse practitioner, or physician assistant (as applicable) is the primary care practitioner